NORTHFIELD, Ill., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that it plans to report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. A press release and supplemental materials will be issued before the market opens. The company will host a webcast and conference call at 9:30am ET/ 8:30am CT to discuss the financial results. Information about Medline’s financial results, including a link to the live webcast, will be available ...

ibex Nicaragua Has Earned Five Great Place to Work Certifications, Underscoring Its World-Class Workplace Culture and Employee Experience ibex Ranked Top 10 Best Workplaces for Service Professionals in the Caribbean and Central America Recognition underscores ibex’s industry-leading culture and world-class employee experience MANAGUA, Nicaragua, Jan. 28, 2026 (GLOBE NEWSWIRE) -- ibex (NASDAQ: IBEX), a leading global provider of business process outsourcing (BPO) and AI-powered customer engagement technol ...

NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- AMC Networks Inc. (NASDAQ: AMCX) will host a conference call to discuss results for the fourth quarter and full year 2025 on Wednesday, February 11, 2026 at 4:30 p.m. Eastern Time. AMC Networks will issue a press release reporting its results after the market closes. The conference call will be webcast live via the company’s website at investors.amcnetworks.com. To access the conference call via telephone, please pre-register for the call to obtain the dial-in num ...

PRINCETON JUNCTION, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- MISTRAS Group (NYSE: MG), a global leader in technology-enabled industrial asset integrity and laboratory testing solutions, today announced several strategic leadership appointments that further strengthen the Company’s governance, financial discipline, and operational execution as it advances its long-term growth strategy. The Company has appointed Eileen Coggins as Executive Vice President, General Counsel, and Corporate Secretary; Istvan Bodo a ...

Core Insights - The upcoming Milan Cortina 2026 Winter Olympics and Paralympics signify a shift in how sports are experienced and interpreted culturally, rather than just in the competition itself [2] Consumer Insights - Consumers are increasingly viewing major sporting events as cultural moments, where identity and personal values play a significant role alongside athletic performance [3] - Nearly 60% of consumers globally believe athletes should express their full identity beyond sports, indicating a demand for brands to communicate with cultural awareness and relevance [4] Brand Strategy - Younger generations are particularly interested in multidimensional narratives of athletes, which include their roles as creators, entrepreneurs, and advocates, suggesting that off-field stories are as influential as on-field actions [5] - For small and medium-sized businesses (SMBs), the focus should be on emotional storytelling that resonates with audiences, rather than competing with elite athletes or official sponsors [6] Marketing Recommendations - Brands should lead with action while also showcasing the human side of athletes, providing context that highlights personality and community [10] - Authentic representation across various demographics is crucial, especially during the Paralympics, where visuals should feel natural and relatable [11] - Emphasizing cultural relevance over Olympic clichés is essential; brands should focus on the emotions evoked by the Games, such as resilience and belonging, rather than just the event itself [12]

Core Insights - SOLOWIN HOLDINGS has received an In-Principle Approval letter for a stablecoin license from the Central Bank of Bahrain for its subsidiary AX Coin, pending final regulatory approval [1][2] Company Overview - SOLOWIN HOLDINGS (NASDAQ: AXG) is a leading financial technology firm established in 2016, focusing on bridging traditional and decentralized finance through secure and compliant financial infrastructure [2] - The company operates through its subsidiaries, including AlloyX Group and AX Coin, and offers integrated digital asset solutions for global investors and institutions [2] - The firm is backed by prominent international institutional investors and aims to manage compliant and transparent digital assets closely linked to the real economy [2] Strategic Goals - The company aims to launch a compliant stablecoin within the regulatory framework and expand AlloyX Group's stablecoin ecosystem across the Middle East and Africa (MEA) region and beyond [2]

NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Perella Weinberg Partners (NASDAQ:PWP), a leading global independent advisory firm, today announced that it plans to release its financial results for the full year and fourth quarter 2025 on Friday, February 6, 2026, before the market opens. Conference Call and Webcast Management will host a conference call and webcast to review Perella Weinberg’s results on the same day at 9:00AM ET. A webcast of the conference call will be available to the public on a listen-on ...

Core Insights - GRI Bio, Inc. announced positive data from its Phase 2a clinical study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF), indicating potential disease-modifying effects and therapeutic differentiation [1][10] Gene Expression and Mechanism - RNA-sequencing data showed significant improvement in genes related to lung injury, myofibroblast activation, and fibrosis progression in GRI-0621 treated subjects compared to placebo, validating previous biomarker findings [2][4] - The treatment demonstrated modulation of differentially expressed genes (DEGs) linked to key disease drivers, supporting a mechanism of fibrosis resolution and tissue repair rather than mere symptomatic management [3][4] Lung Regeneration Evidence - GRI-0621 treatment was associated with repair of the alveolar basement membrane and transition of AT2 to AT1 epithelial cells, indicating true lung regeneration rather than just slowing disease progression [5][6] - Earlier data indicated changes in type IV collagen serum biomarkers, suggesting an alveolar repair mechanism, which is now supported by new gene expression findings [6] Consistency Across Data - The new results reinforce previously announced topline data, showing that GRI-0621 treatment led to decreased neutrophil activity, reduced synthesis of fibrillar collagens, and lower levels of pro-fibrotic cytokines [8][9] - The treatment was well-tolerated, differentiating it from existing options that primarily slow disease decline while having significant side effects [7][10] Clinical Study Outcomes - The Phase 2a study met its primary endpoint with favorable safety and tolerability, and multiple secondary endpoints indicative of disease-modifying activity were achieved [12] - Improvements were noted in forced vital capacity (FVC), with twice as many GRI-0621-treated subjects experiencing no decline in FVC at 12 weeks compared to standard care [12]

Core Insights - The study led by the National Cancer Institute (NCI) demonstrated a median progression-free survival (PFS) of 9.6 months for the investigational drug PDS01ADC in patients with metastatic castration-resistant prostate cancer (mCRPC) [1][2] - The combination therapy showed a median PSA decline of 40%, with 6 out of 16 patients achieving more than a 50% decline [2] - PDS Biotech aims to advance PDS01ADC as a key component of its immuno-oncology pipeline, reinforcing its potential to enhance existing therapies across various solid tumor types [3] Company Overview - PDS Biotechnology Corporation is a late-stage immunotherapy company focused on transforming immune responses to cancer [4] - The company has initiated a pivotal clinical trial for its lead program targeting advanced HPV16-positive head and neck squamous cell cancers [4] - PDS Biotech's lead investigational therapy, PDS0101 (Versamune HPV), is being developed in combination with standard immune checkpoint inhibitors and PDS01ADC [4]

Core Insights - The FDA has granted Breakthrough Therapy Designation to NXC-201 for the treatment of relapsed/refractory AL Amyloidosis based on positive interim clinical results from the NEXICART-2 Phase 2 trial [1][3][4] Company Overview - Immix Biopharma, Inc. is recognized as the global leader in relapsed/refractory AL Amyloidosis, focusing on developing innovative therapies for this condition [9] - The company’s lead candidate, NXC-201, is a sterically-optimized BCMA-targeted CAR-T cell therapy designed to filter out non-specific activation and teach the immune system to eliminate toxic light chains [8][9] Clinical Development - NEXICART-2 is an ongoing multi-site U.S. Phase 2 clinical trial aimed at enrolling 40 patients to evaluate the efficacy of NXC-201 in relapsed/refractory AL Amyloidosis [5] - Final data from the NEXICART-2 trial is expected to be released this year, followed by a planned Biologics License Application (BLA) submission [1][4] Market Context - The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is projected to grow at a rate of 12% per year, reaching approximately 38,500 patients by 2026 [6] - The AL Amyloidosis market was valued at $3.6 billion in 2017 and is anticipated to reach $6 billion by 2025 [7]